MannKind Corporation to Hold 2019 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2020
February 18 2020 - 9:00AM
MannKind Corporation (NASDAQ:MNKD) will release
its 2019 fourth quarter and full year financial results and its
management will host a conference call to discuss the financial
results and corporate updates at 9:00 AM (Eastern Time) on Tuesday,
February 25, 2020.
Presenting from the Company will be its Chief
Executive Officer, Michael Castagna and Chief Financial Officer,
Steven Binder.
To participate in the live call by telephone,
please dial (800) 289-0438 or (323) 794-2423 and use the
participant passcode: 1233728. Those interested in listening to the
conference call live via the Internet may do so by visiting the
Company's website at http://www.mannkindcorp.com under News &
Events.
A telephone replay of the call will be
accessible for approximately 14 days following completion of the
call by dialing (844) 512-2921 or (412) 317-6671 and use the
participant passcode: 1233728. A replay will also be available on
MannKind's website for 14 days.
About MannKind Corporation
MannKind Corporation (NASDAQ: MNKD) focuses on
the development and commercialization of inhaled therapeutic
products for patients with diseases such as diabetes and pulmonary
arterial hypertension. MannKind is currently commercializing
Afrezza® (insulin human) Inhalation Powder, the Company’s first
FDA-approved product and the only inhaled rapid-acting mealtime
insulin in the United States, where it is available by prescription
from pharmacies nationwide. MannKind is headquartered in
Westlake Village, California, and has a state-of-the art
manufacturing facility in Danbury, Connecticut. The Company also
employs field sales and medical representatives across the U.S. For
further information, visit www.mannkindcorp.com.
Company Contact: Phone:
(818) 661-5000 Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024